52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Quest Diagnostics Introduces New Covid-19 Semi-Quantitative Serology Test Service
Quest Diagnostics Reports Board Leadership Changes
Quotient Limited Announces Manuel Mendez As Chief Executive Officer
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs). Its Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology businesses, which offers solutions for healthcare providers. The Company's services are provided under the Quest Diagnostics brand, but it also provides services under other brands, including AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum and Care360.
500 Plaza Dr
Stephen H. Rusckowski
Chairman of the Board, President, Chief Executive Officer
Mark J. Guinan
Chief Financial Officer, Executive Vice President
James E. Davis
Executive Vice President, General Diagnostics
Michael E. Prevoznik
Senior Vice President, General Counsel
Catherine T. Doherty
Senior Vice President, Group Executive - Clinical Franchise Solutions and Marketing
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Medical device maker Quest Diagnostics Inc's quarterly profit beat estimates on Thursday, boosted by robust demand for its COVID-19 testing services as coronavirus infections surged in the United States.
Quest Diagnostics Inc on Thursday posted a near 129% rise in quarterly profit on robust demand for the clinical lab operator's COVID-19 testing services.
* U.S. FDA SAYS AUTHORIZES FIRST COVID-19 AND FLU COMBINATION TEST FOR USE WITH HOME-COLLECTED SAMPLES
Quest Diagnostics Inc <DGX.N> said on Tuesday the nationwide surge in coronavirus cases has led to a slight increase in turnaround time for its COVID-19 testing.
Quest Diagnostics Inc raised its full-year earnings expectations on Thursday after a strong quarterly beat and forecast robust demand for COVID-19 tests during the fall season and into 2021.
Quest Diagnostics Inc reported a 164% rise in third-quarter profit on Thursday, as demand for tests offered by the clinical lab operator recovered on easing of COVID-19 related restrictions.
Drugmakers around the world are rushing to develop treatments for COVID-19, the respiratory disease caused by the novel coronavirus that has killed hundreds of thousands. Several companies are developing antibody treatments, similar to Regeneron Pharmaceutical Inc's treatment...
Walmart Inc said on Tuesday it would run a pilot project to deliver self-collection test kits for coronavirus through automated drones at customers' doorsteps.
Corona Capital is a column updated throughout the day by Breakingviews columnists around the world with short, sharp pandemic-related insights.
Quest Diagnostics <DGX.N> on Thursday raised its full-year revenue and profit forecast, benefiting from growing demand for its non-COVID-19 testing services.
Florida on Tuesday cut ties with Quest Diagnostics Inc as the medical device maker failed to share the results of nearly 75,000 COVID-19 tests dating back to April with the state health department in a timely manner due to a technical issue.
(The story corrects to say that partnership with Mayo and Quest is ongoing in paragraph 3 on story from Aug 18)
Quest Diagnostics Inc <DGX.N> said on Thursday it expects to cut week-long turnaround times for COVID-19 tests by more than half to get to "acceptable" levels by September, responding to concerns that slow testing is hampering the U.S. response.
Quest Diagnostics Inc said on Thursday it expects to get turnaround times for COVID-19 tests to "acceptable" levels by this September by boosting capacity and prioritizing the most at-risk patients.
Quest Diagnostics Inc said on Monday the turnaround for COVID-19 tests it is conducting in the United States has lengthened, with non-prioritized patients waiting a week or more on average for their results.
Quest Diagnostics reported preliminary second-quarter revenue above analysts' estimates on Monday, largely due to growing demand for its COVID-19 testing services.
* QUEST DIAGNOSTICS SAYS DEMAND FOR COVID-19 MOLECULAR DIAGNOSTIC TESTING CONTINUES TO SURGE, CAUSING FURTHER DELAYS IN TURNAROUND TIMES
* HUMANA TO OFFER LABCORP AT-HOME COVID-19 TEST COLLECTION AND COLLABORATE WITH WALMART AND QUEST DIAGNOSTICS TO OFFER DRIVE-THRU TESTING FOR HUMANA MEMBERS Source text for Eikon: Further company coverage:
* QUEST DIAGNOSTICS TO EXPAND IN INDIANA WITH ACQUISITION OF OUTREACH LAB BUSINESSES OF COMMUNITY HEALTH NETWORK AND ASCENSION ST. VINCENT NOW SERVICED THROUGH MID AMERICA CLINICAL LABORATORIES
Quest Diagnostics said on Wednesday it saw a higher recovery in its testing volumes in the United States where state and local governments were slowly lifting restrictions after the coronavirus lockdowns.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.